FDA Approval Of Gilead’s Sofosbuvir Shows Flexibility On HCV Combos
This article was originally published in The Pink Sheet Daily
Executive Summary
Pricing means an $84,000 cost of therapy for some HCV patients, but $168,000 for others. The nucleotide polymerase inhibitor will be dosed with ribavirin but eliminates interferon for patients with genotypes 2 and 3, making it the first all-oral therapeutic regimen.